Form 4: J&J Legal Chief Exercises Options, Sells Shares

Johnson & Johnson's EVP, Chief Legal Officer, Elizabeth Forminard, exercised stock options and subsequently sold a portion of the acquired shares to cover tax liabilities.

Summary

• Elizabeth Forminard, EVP, Chief Legal Officer of Johnson & Johnson, exercised 8,921 employee stock options on February 5, 2026.
• The options were exercised at a price of $129.51 per share.
• Following the exercise, Forminard beneficially owned 21,774 shares of common stock.
• Concurrently, Forminard disposed of 6,226 shares of common stock to cover tax liabilities associated with the option exercise.
• These shares were sold at a weighted average price of $237.9 per share, with prices ranging from $237.89 to $237.935.
• After these transactions, Forminard's direct beneficial ownership of Johnson & Johnson common stock stands at 15,548 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine insider transaction involving the exercise of options and a sale for tax purposes, which does not typically signal a significant change in company fundamentals or outlook.

Positives

• Exercise of employee stock options indicates confidence in the company's long-term value by management.
• The exercise price of $129.51 is significantly lower than the sale price of $237.9, indicating a substantial gain for the executive.

Negatives

• The sale of 6,226 shares, even for tax purposes, reduces the executive's direct ownership stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as option exercises followed by sales for tax purposes, are common across the pharmaceutical and consumer health industries. These transactions typically reflect standard executive compensation practices rather than a specific market signal about the company's immediate prospects. Johnson & Johnson's peers often see similar filings from their executives as part of their long-term incentive plans.

Comparison to Industry Standards

• The exercise of stock options and subsequent sale of shares for tax withholding is a standard practice for executives across major corporations, including those in the healthcare sector like Pfizer, Merck, and Abbott Laboratories.
• The transaction size for Elizabeth Forminard, involving 8,921 shares exercised and 6,226 shares sold, is typical for a senior executive at a large-cap company like Johnson & Johnson, and does not deviate significantly from similar filings observed from executives at comparable companies.
• The substantial difference between the exercise price ($129.51) and the market sale price ($237.9) highlights the long-term value creation for executives through equity compensation, a common feature in competitive executive packages globally.

Related Party Transactions

• The reported transactions involve an executive (Elizabeth Forminard) and the company (Johnson & Johnson), which constitutes a related party transaction as per SEC regulations.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not directly impact the company's operational performance or financial health. It provides transparency into executive stock ownership changes.
• Employees: No direct impact on general employees, but it highlights the structure of executive incentive compensation.
• Management: The transaction allows the executive to realize value from vested stock options while maintaining a significant ownership stake.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive exercised stock options and sold shares to cover tax liabilities. Such transactions are common and generally do not indicate a change in the company's fundamental prospects or warrant a shift in investment strategy. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to alter an existing investment thesis for Johnson & Johnson.

Keywords

Johnson & Johnson, JNJ, Insider Trading, Form 4, Stock Options, Executive Compensation, Elizabeth Forminard, Share Sale, Tax Withholding